预约演示
更新于：2026-08-21
Terbinafine
特比萘芬
更新于：2026-08-21
概要
基本信息
简介特比萘芬是一种小分子药物，通过阻断 SQLE 发挥其抑制作用，SQLE 是真菌细胞膜的主要成分麦角甾醇生物合成中的关键酶。由于这种抑制作用，特比萘芬攻击真菌细胞膜，导致真菌过早死亡。特比萘芬已在临床领域用于治疗一系列真菌感染，包括甲癣和股癣。该药由GSK研发，并于1998年4月获得FDA批准。 |
药物类型 小分子化药 |
别名 (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalene methanamine、(E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine、Terbinafine (USAN/INN) + [8] |
靶点 |
作用方式 抑制剂 |
作用机制 SQLE抑制剂(角鲨烯单加氧酶抑制剂) |
原研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)临床前 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H25N |
InChIKeyDOMXUEMWDBAQBQ-WEVVVXLNSA-N |
CAS号91161-71-6 |
关联
23
项与 特比萘芬 相关的临床试验CTRI/2024/01/061561
Randomised control trial to study the effectiveness of Tablet Fluconazole, Capsule Itraconazole and Tablet Terbinafine in Superficial Dermatophytosis - NIL
IRCT20210611051539N4
Formulation design and evaluation of the effect of hyaluronic acid hydrogel loaded with terbinafine lipid nanostructures in the treatment of patients with onychomycosis
CTRI/2023/06/054377
Comparative Clinical Study To Evaluate The Efficacy Of Dadru Gajendra Sinh Lepa And Terbinafine Ointment In Management Of Dadru Kushtha W.R.T Tinea Cruris . - NIL
100 项与 特比萘芬 相关的临床结果
登录后查看更多信息
100 项与 特比萘芬 相关的转化医学
登录后查看更多信息
100 项与 特比萘芬 相关的专利（医药）
登录后查看更多信息
3,788
项与 特比萘芬 相关的文献（医药）2026-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Recalcitrant tinea infections due to
Trichophyton indotineae
in the United States (2025–2026): a retrospective case series identified by real-time PCR
Article
作者: Bakotic, Wayne L. ; Lincoln, Sara A. ; Wang, Tong ; Gupta, Aditya K.
OBJECTIVES:
To highlight the clinical characteristics and challenges in managing T. indotineae infections in the United States and to introduce the utility of rapid real-time PCR (qPCR) diagnosis.
METHODS:
Records from a molecular diagnostics laboratory (Bako Diagnostics, GA, USA) were retrospectively reviewed for T. indotineae detections between May 2025 and January 2026. Cases were identified using a novel single-plex qPCR assay and confirmed by sequencing of the internal transcribed spacer region. The squalene epoxidase gene (SQLE) was sequenced to assess terbinafine resistance. A survey was distributed to treating physicians to collect information on recent international travel, household transmission, clinical features, immunosuppressive medications or conditions, and treatment history.
RESULTS AND CONCLUSIONS:
All patients (median age: 54; 3 males and 2 females) reported recent travel to India or Nepal, except one, who was the spouse of a patient who had traveled to India. Two different SQLE substitutions were detected, F397L (N = 2) and L393F (N = 1), which are common among terbinafine-resistant T. indotineae isolates found globally. Potential gaps in clinical management - attributed to treatment initiation prior to confirmatory diagnosis of T. indotineae - were identified. These gaps include the use of topical corticosteroids, lack of itraconazole use (100-200 mg/day for 6-8 weeks or longer) as first-line treatment, and prescribing fixed, short treatment durations. In T. indotineae cases, these practices may increase the risk of disease recurrence and domestic spread. Current clinical recommendations are summarized herein, highlighting the utility of this novel qPCR assay for real-time treatment decision-making.
2026-12-01Current Fungal Infection Reports
Updates on Chromoblastomycosis: Evolving Insights in Clinical Management and Therapeutic Strategies
Article
作者: Agudelo Higuita, Nelson Iván ; Henao-Martínez, Andrés F ; Popovic, Katarina ; de Souza, Elton Bill Amaral ; Teixeira, Marcus de Melo ; Rakotoarisaona, Mendrika
Purpose of Review:
The aim of this review is to provide an in-depth overview of chromoblastomycosis, with emphasis on emerging management strategies and therapeutic options, and to underscore potential gaps in the literature and priorities for future research.
Recent Findings:
Among the newer triazoles, posaconazole has demonstrated greatest therapeutic potential in the treatment of chromoblastomycosis, including for severe and refractory disease. Adjunctive immunomodulatory therapies such as glucan, imiquimod, and acitretin have shown potential as well. Several novel and repurposed agents also have potential activity against dematiaceous fungi, including tricyclazole, HIV peptidase inhibitors, 1,10-phenanthroline-5,6-dione, and benzimidazoles. A recently proposed combination protocol with debulking, intralesional amphotericin B, and oral terbinafine (DAT protocol) achieved cure in all 16 included patients in a 2025 case series. While excisional surgery remains the preferred physical therapeutic modality, several reports have shown favorable results with both photodynamic and heat therapy.
Summary:
Chromoblastomycosis continues to pose a therapeutic challenge, requiring prolonged antifungal therapy often combined with physical therapeutic modalities. Improved access to diagnostics and early intervention remain essential to reducing global disease burden.
2026-12-01BRAZILIAN JOURNAL OF MICROBIOLOGY
Antibiofilm activity of terbinafine, itraconazole and their combination against Sporothrix brasiliensis yeast-like form’s biofilms
Article
作者: Sant Ana, Leticia A M ; Queiroz-Telles, Flavio ; Santos, Germana D ; Cognialli, Regielly C R ; Svidzinski, Terezinha I E ; Sprenger, Anarosa B ; Vicente, Vania A ; Razzolini, Emanuel ; Geraldo, Marlon R ; Silva, Andreia B
Abstract:
Sporothrix brasiliensis
biofilms represent a challenge in the treatment of sporotrichosis due to their structural complexity and antifungal resistance. This study evaluated the efficacy of terbinafine (TERB) and itraconazole (ITZ), and their synergism against biofilms of yeast-like forms of
S. brasiliensis
. Seven clinical strains were analyzed for biofilm formation and structural alterations using spectrophotometry, confocal laser scanning microscopy (CLSM), and scanning electron microscopy (SEM). The treatment in early-stage biofilms (3 hours) exhibited greater susceptibility to ITZ, whereas mature biofilms (144 hours) responded better to TERB. Statistical analysis confirmed significant differences among treatments (
p
< 0.016) and a dose-dependent effect, although no considerable synergistic interaction was observed between ITZ and TERB. CLSM and SEM analyses revealed reduced biofilm formation and adhesion, biofilm disorganization, and cellular morphological changes following exposure to antifungals, both individually and in combination. TERB was significantly more effective in eradicating mature biofilms than ITZ or the combination (
p
< 0.001). These findings reinforce the need for early intervention in sporotrichosis treatment and suggest that TERB may be a valuable alternative for biofilm-associated infections.
100 项与 特比萘芬 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 股癣 | 美国 | 2006-07-24 | |
| 糠疹 | 美国 | 1998-04-29 | |
| 癣 | 美国 | 1998-04-29 | |
| 体癣 | 美国 | 1998-04-29 | |
| 足癣 | 美国 | 1998-04-29 | |
| 花斑癣 | 美国 | 1998-04-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 甲癣 | 临床3期 | 美国 | 2006-12-01 | |
| 甲癣 | 临床3期 | 加拿大 | 2006-12-01 | |
| 甲癣 | 临床3期 | 法国 | 2006-12-01 | |
| 甲癣 | 临床3期 | 德国 | 2006-12-01 | |
| 甲癣 | 临床3期 | 冰岛 | 2006-12-01 | |
| 真菌病 | 临床1期 | - | 2011-02-24 | |
| 肝细胞癌 | 临床前 | 中国 | 2025-09-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 30 | 顧鹹齋壓齋繭簾襯獵齋(艱艱選壓齋鑰窪淵鬱選) = 鹽遞衊簾襯醖鹽製獵築 獵鹽簾築壓窪鏇齋積廠 (積壓夢廠糧蓋鹹鏇窪願, 選顧網夢遞膚鏇襯遞淵 ~ 鑰繭遞鹹築鑰鏇淵顧膚) 更多 | - | 2019-09-24 | |||
临床3期 | 290 | (Terbinafine) | 選壓襯窪觸獵鹽簾夢鹹 = 觸顧鏇製憲鏇糧獵構願 壓範獵鏇鹽齋夢鹽選積 (鏇齋構鹽醖憲艱膚積壓, 遞糧艱鹹窪願鏇憲壓構 ~ 積顧憲襯選襯顧夢膚廠) 更多 | - | 2013-12-27 | ||
Terbinafine Placebo (Placebo) | 選壓襯窪觸獵鹽簾夢鹹 = 築膚憲選獵築醖憲範憲 壓範獵鏇鹽齋夢鹽選積 (鏇齋構鹽醖憲艱膚積壓, 觸夢構範選願窪選遞獵 ~ 鑰繭鬱鏇構廠壓壓網網) 更多 | ||||||
临床3期 | 518 | (Terbinafine 24 w) | 構簾範齋衊鑰夢蓋醖憲 = 衊觸築積鹽糧蓋蓋膚憲 廠廠夢廠獵願憲網蓋觸 (願鏇糧鏇網觸鹹積艱廠, 鑰憲壓膚簾顧憲衊繭觸 ~ 遞窪夢夢壓鑰築齋憲蓋) 更多 | - | 2011-04-20 | ||
placebo (Vehicle 24 w) | 構簾範齋衊鑰夢蓋醖憲 = 獵觸選窪獵餘膚觸鑰醖 廠廠夢廠獵願憲網蓋觸 (願鏇糧鏇網觸鹹積艱廠, 願鹹艱製齋積齋窪獵衊 ~ 膚網襯鬱製蓋餘窪夢鑰) 更多 | ||||||
临床3期 | 526 | (Terbinafine 24 Weeks) | 築鹽選選鬱顧齋艱醖遞 = 壓齋顧艱夢衊夢繭鏇淵 繭壓廠鑰鬱憲製夢夢構 (壓鑰願顧夢窪範醖鏇範, 鏇簾鹽襯醖蓋繭鹽齋餘 ~ 範憲築積鑰範淵艱夢糧) 更多 | - | 2011-04-19 | ||
placebo (Vehicle 24 Weeks) | 築鹽選選鬱顧齋艱醖遞 = 膚膚蓋網夢遞積窪餘觸 繭壓廠鑰鬱憲製夢夢構 (壓鑰願顧夢窪範醖鏇範, 憲憲艱襯觸餘願選艱齋 ~ 鑰鬱選鑰鏇獵獵廠膚鑰) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用